Skip to content

Based on "two-heart theory" to explore the clinical study of "eliminating phlegm and removing blood stasis, soothing liver and regulating qi" in the treatment of chronic heart failure

Based on "two-heart theory" to explore the clinical study of "eliminating phlegm and removing blood stasis, soothing liver and regulating qi" in the treatment of chronic heart failure

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085018
Enrollment
Unknown
Registered
2024-05-29
Start date
2022-08-03
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

control group:Western medicine
experimental group:Western medicine combined with Chinese medicine

Sponsors

Liyang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Voluntary participation and informed consent; (2) Age 18-90 years old, gender unlimited; (3) A history of chronic heart failure for more than 3 months or clinical findings of heart failure symptoms for more than 3 months; (4) NYHA cardiac function grade ?-?; (5) EF < 50% measured by Simpson method; (6) At least 2 weeks of standardized drug therapy; (7) TCM syndrome is consistent with Qi deficiency and blood stasis;

Exclusion criteria

Exclusion criteria: (1) does not meet the inclusion criteria; (2) Heart failure caused by non-cardiogenic causes, congenital heart disease, acute heart failure, or heart failure after acute myocardial infarction; (3) Patients who plan to undergo coronary revascularization therapy and cardiac resynchronization therapy within 8 weeks; (4) unrepaired valvular heart disease with myocarditis, aneurysm, left ventricular outflow tract obstruction, and significant hemodynamic changes; (5) Patients with severe primary diseases of liver and kidney and serious abnormal liver and kidney function; (6) Cancer patients, psychiatric patients, patients with serious diseases of the blood, nervous system, endocrine system; (7) Patients with cardiogenic shock, uncontrolled malignant arrhythmias, sinus or atrioventricular block of grade II type II or above without pacemaker therapy, progressive aggravation of unstable angina pectoris or acute myocardial infarction; (8) Patients with uncontrolled hypertension with systolic blood pressure of 180/mmHg and/or diastolic blood pressure of 110mmHg; Systolic blood pressure < 90mmHg and/or diastolic blood pressure < 60mmHg; (9) Patients participating in clinical trials of other drugs; (10) Pregnant or preparing to become pregnant and lactating women; (11) People who are allergic, or have been known to be allergic to therapeutic drugs.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;Left Ventricular Ejection Fraction;Minnesota Quality of Life Scale Rating;Hamilton Depression Scale;Changes in Traditional Chinese Medicine Syndrome Points and Therapeutic Effects;

Secondary

MeasureTime frame
TNF-a;interleukin 6;6-minute walking test ;5-HT;CRP;

Countries

China

Contacts

Public ContactChunhui Huang

Liyang Hospital of Traditional Chinese Medicine

862592413@qq.com+86 157 0615 6726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026